MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML

Leukemia

Volumn 26, Issue 3, 2012, Pages 443-450

  Carter, B Z ^a   Mak, D H ^a   Shi, Y ^a   Fidler, J M ^b   Chen, R ^a   Ling, X ^a   Plunkett, W ^a   Andreeff, M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MyeloRx LLC   (United States)

Author keywords

AML and AML stem cells; Mcl 1; microenvironment; MRx102; triptolide; XIAP

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BENDAMUSTINE; CD34 ANTIGEN; CD38 ANTIGEN; CLOFARABINE; CYTARABINE; ETOPOSIDE; FLUDARABINE; IDARUBICIN; IMATINIB; MITOXANTRONE; MRX 102; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PIMASERTIB; PONATINIB; PROTEIN MCL 1; RNA; RUXOLITINIB; SORAFENIB; TRIPTOLIDE; TRITIUM; UNCLASSIFIED DRUG; URIDINE; VORINOSTAT; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTILEUKEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; DRUG DOSE INCREASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LOW DRUG DOSE; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA SYNTHESIS; STEM CELL; TREATMENT OUTCOME; TRIPTERYGIUM; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BONE MARROW; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; PHENANTHRENES; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSCRIPTION, GENETIC; TUMOR MICROENVIRONMENT; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84857995858     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.246     Document Type: Article

References (30)

1. Shamon LA, Pezzuto JM, Graves JM, Mehta RR, Wangcharoentrakul S, Sangsuwan R et al. Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from tripterygium wilfordii. Cancer Lett 1997; 112: 113-117. (Pubitemid 27067433)
2. Kiviharju TM, Lecane PS, Sellers RG, Peehl DM. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res 2002; 8: 2666-2674. (Pubitemid 34856355)
3. Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z et al. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 2006; 108: 630-637. (Pubitemid 44061364)
4. Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM et al. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells. Mol Cancer Ther 2009; 8: 2509-2516.
5. Tengchaisri T, Chawengkirttikul R, Rachaphaew N, Reutrakul V, Sangsuwan R, Sirisinha S. Antitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamsters. Cancer Lett 1998; 133: 169-175. (Pubitemid 29069041)
6. Lee KY, Chang W, Qiu D, Kao PN, Rosen GD. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem 1999; 274: 13451-13455.
7. Chang WT, Kang JJ, Lee KY, Wei K, Anderson E, Gotmare S et al. Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem 2001; 276: 2221-2227. (Pubitemid 32109705)
8. Frese S, Pirnia F, Miescher D, Krajewski S, Borner MM, Reed JC et al. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene 2003; 22: 5427-5435. (Pubitemid 37072197)
9. Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT et al. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 2008; 111: 3742-3750.
10. Yang S, Chen J, Guo Z, Xu XM, Wang L, Pei XF et al. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2003; 2: 65-72.
11. Lee KY, Park JS, Jee YK, Rosen GD. Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)- induced apoptosis by inhibition of NF-kappaB activation. Exp Mol Med 2002; 34: 462-468. (Pubitemid 36114364)
12. Qiu D, Zhao G, Aoki Y, Shi L, Uyei A, Nazarian S et al. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem 1999; 274: 13443-13450.
13. Westerheide SD, Kawahara TL, Orton K, Morimoto RI. Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J Biol Chem 2006; 281: 9616-9622. (Pubitemid 43864680)
14. Lou YJ, Jin J. Triptolide down-regulates bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells. Leuk Lymphoma 2004; 45: 373-376. (Pubitemid 38181443)
15. Zhang C, Cui GH, Liu F, Wu QL, Chen Y. Inhibitory effect of triptolide on lymph node metastasis in patients with non-Hodgkin lymphoma by regulating SDF-1/CXCR4 axis in vitro. Acta Pharmacol Sin 2006; 27: 1438-1446. (Pubitemid 44630311)
16. Pan J. RNA polymeraseFan important molecular target of triptolide in cancer cells. Cancer Lett 2010; 292: 149-152.
17. Vispe S, DeVries L, Creancier L, Besse J, Breand S, Hobson DJ et al. Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of shortlived mRNA. Mol Cancer Ther 2009; 8: 2780-2790.
18. Titov DV, Gilman B, He QL, Bhat S, Low WK, Dang Y et al. XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol 2011; 7: 182-188.
19. Lu L, Kanwar J, Schmitt S, Cui QC, Zhang C, Zhao C et al. Inhibition of tumor cellular proteasome activity by triptolide extracted from the Chinese medicinal plant 'thunder god vine'. Anticancer Res 2011; 31: 1-10.
20. Kupchan SM, Court WA, Dailey Jr RG, Gilmore CJ, Bryan RF. Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J Am Chem Soc 1972; 94: 7194-7195.
21. Fidler JM, Li K, Chung C, Wei K, Ross JA, Gao M et al. PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol Cancer Ther 2003; 2: 855-862.
22. Kitzen JJ, de Jonge MJ, Lamers CH, Eskens FA, van der BD, van DL et al. Phase i dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer 2009; 45: 1764-1772.
23. Harousseau JLH, Dombret HD, Pigneux AP, Michallet MM, Brandely MB. Phase I study of F60008, a triptolide derivative, in patients with refractory or relapsing acute leukemias. 13th Congress of the European Hematology Association (EHA) 2008, Ref Type: Abstract.
24. Ling X, Konopleva M, Zeng Z, Ruvolo VR, Stephens LC, Schober W et al. The novel triterpenoid C-28 methyl ester of 2-cyano-3,12- dioxooleana-1,9-dien-28- oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling. Cancer Res 2007; 67: 4210-4218. (Pubitemid 46815067)
25. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002; 62: 3603-3608. (Pubitemid 34728832)
26. Martin S, Reutelingsperger C, McGahon A, Rader J, van Schie R, LaFace D et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and ABL. J Exp Med 1995; 182: 1545-1556.
27. Carter BZ, Mak D, Schober WD, Cabreira-Hansen M, Beran M, McQueen T et al. Regulation of survivin expression through bcrabl/ MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib responsive CML cells. Blood 2006; 107: 1555-1563. (Pubitemid 43242394)
28. Carter BZ, Mak DH, Shi Y, Schober WD, Wang RY, Konopleva M et al. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle 2006; 5: 2223-2229. (Pubitemid 44546558)
29. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-2307.
30. Fidler J, An J, Musser JH, Mak D, Carter BZ, Andreeff M. Preclinical development of triptolide derivative MRx102 as a therapeutic agent for acute myeloid leukemia. Blood 2010; 11: 1340-1341.